Work

A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.3001

Authors: Matthew P. Goetz, Anthony W. Tolcher, Paul Haluska, Kyriakos P. Papadopoulos, Charles Erlichman, Muralidhar Beeram, Janet Lensing, Drew Warren Rasco, Julian R. Molina, Rebecca Arcos, Peipei SHI, Palaniappan Kulanthaivel, Celine Pitou, Lynette Mulle, Edward Michael Chan, Amita Patnaik

Institutions: Mayo Clinic, South Texas Accelerated Research Therapeutics, Eli Lilly (United States)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2619332452

Cites:

Cited by: 7

Related to: 10